Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2017-09-06 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext Announces that the DSMB Recommends Continuing the Ongoing Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A
Regulatory Filings Classification · 1% confidence The document is a news release dated September 6, 2017, announcing that the Data Safety Monitoring Board (DSMB) recommended continuing the Phase 3 clinical trial of PXT3003. It contains key highlights about the trial status, safety profile, and future expectations, but it is not a comprehensive financial report (like 10-K or IR) nor is it a transcript of a call. It is an announcement of operational/clinical progress. Since it is a specific operational update that doesn't fit perfectly into the financial categories (10-K, ER, IR, CAP, etc.), and it is a formal news release disseminated via DGAP, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for important, non-standard corporate news, or potentially an 'Earnings Release' (ER) if we interpret 'Earnings' broadly as 'Periodical Update', but RNS is safer for clinical trial updates. Given the options, RNS (Regulatory Filings) is the most appropriate general category for this type of corporate news announcement that isn't a formal financial report or a specific management/board change.
2017-09-06 English
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is structured as a press release announcing a specific operational update regarding a clinical trial (DSMB recommendation to continue Phase 3 trial for PXT3003). It is not a comprehensive annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a presentation (IP). While it discusses clinical data, its primary function is a timely, non-periodic announcement of a development milestone. This type of announcement, which is often regulatory in nature but doesn't fit the specific financial report codes, typically falls under general Regulatory Filings (RNS) or sometimes an Earnings Release if it were tied to quarterly results. Given the focus on a clinical trial update and the format being a standard press release, RNS is the most appropriate general regulatory/announcement category, as it is not a specific financial report or management change announcement.
2017-09-06 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is titled "*Communiqué de presse*" (Press Release) and announces a specific, time-sensitive corporate event: the Data Safety Monitoring Board (DSMB) recommending the continuation of the Phase 3 clinical trial (PLEO-CMT) for drug PXT3003. It provides details about the trial, quotes the CEO, and includes standard 'About the Company' and 'Contacts' sections. This format is characteristic of an initial announcement of material, non-financial news, which aligns best with an Earnings Release (ER) if it were financial, but since it is clinical/operational news released via press release, it fits the general category of a significant corporate update. However, none of the definitions perfectly capture a clinical trial update press release. Given the options, it is a general corporate announcement. It is not a full financial report (10-K, IR), a transcript (CT), or a management discussion (MDA). It is a formal announcement of a key operational milestone. In the absence of a specific 'Clinical Trial Update' code, the closest fit for a formal, non-financial, material announcement that isn't explicitly covered elsewhere (like DIRS, DIV, MANG) is often categorized under general regulatory/corporate announcements. Since it is a press release announcing a major operational milestone, and not just announcing the publication of a report (RPA), it is best classified as a general Regulatory Filing (RNS) as a fallback for significant, non-standard announcements, or potentially ER if the database treats all major periodic updates as such. Given the context of clinical trial progress, which is material information, RNS serves as the best catch-all for significant, non-standard corporate news releases.
2017-09-06 French
Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference
Regulatory Filings Classification · 1% confidence The document is a short news release dated September 5, 2017, announcing that Pharnext management will present at the 'Rodman & Renshaw 19th Annual Global Investment Conference' on September 12, 2017. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing results (ER). It is an announcement about management's participation in an investor-focused event, which aligns best with providing information to investors about upcoming corporate activities. Since it is an announcement about management presenting corporate information to investors, it is most closely related to Investor Presentation (IP) or potentially a general Regulatory Filing (RNS). Given the context of presenting a 'corporate overview' at an investment conference, 'Investor Presentation (IP)' is a strong candidate, although the document itself is just the announcement of the presentation, not the presentation slides. However, since the core purpose is communicating corporate/strategy updates to investors, and it's not a standard earnings release or formal report, 'Investor Presentation (IP)' captures the intent better than the generic 'RNS', especially as it details the event where the presentation will occur. If the document were the actual presentation slides, IP would be certain. As it is an announcement *about* a presentation, it functions as a precursor/related communication. Given the options, and recognizing this is a standard announcement type often associated with investor outreach, I will classify it as IP, acknowledging the 'Menu vs Meal' rule suggests RPA/RNS for announcements, but IP is more specific to the *content* being announced (a corporate overview presentation). Since it is an announcement of an event where an overview will be given, and not an announcement of a report publication (RPA), RNS is the safest fallback, but IP describes the nature of the upcoming communication. Let's re-evaluate based on the 'Menu vs Meal' rule: This is an announcement about an upcoming presentation, not the publication of a formal report (10-K, IR, ER). It is a general corporate news item disseminated via DGAP. It doesn't fit DVA, DIV, DIRS, etc. It is an announcement of management activity related to investor relations. Since it is not announcing the publication of a formal report, RPA is less fitting. RNS (Regulatory Filings / General regulatory announcements) is the most appropriate fallback for specific corporate news that doesn't fit the other categories, especially when it's an announcement about future events rather than the release of a document itself. I will use RNS as the most accurate general classification for this type of corporate news release.
2017-09-05 English
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that company management will present a corporate overview at the 'Rodman & Renshaw 19th Annual Global Investment Conference' on a specific date. This type of announcement, detailing participation in an external investor conference where management will present company strategy and financials, aligns best with the Investor Presentation (IP) category, as the core purpose is to communicate with investors, even if the presentation itself hasn't happened yet. It is not a full report (10-K, IR), a transcript (CT), or a simple earnings release (ER). Since it is an announcement about an upcoming investor event where a presentation will occur, IP is the most fitting classification.
2017-09-05 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that the company's management team will be presenting at an external investment conference ('Rodman & Renshaw 19th Annual Global Investment Conference'). This type of announcement, which details participation in investor-facing events, is best classified as an Investor Presentation (IP) announcement or related material, as it is designed to communicate company strategy and financials to potential investors at a specific event. Since the document itself is an announcement about future participation rather than the presentation slides or a transcript, it strongly aligns with the purpose of an Investor Presentation (IP) material, even if it's just the notice. Given the options, 'IP' (Investor Presentation) is the most fitting category for an announcement detailing management's plan to present company information at an investment conference.
2017-09-05 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.